Answers are grounded in this paper and cite their sources.
Tuberculosis is a highly contagious disease (global 50% prevalence), especially in lowresource areas where adequate treatment is limited.No current vaccine has shown efficacy after infancy.Objectives: The primary outcome was to determine if newly available vaccines were effective in providing immunity from morbidity associated with Tuberculosis.The protocol for this review is published on Prospero and can be located by using the following record number, CRD42015017238.Search methods: Searches of the Cochrane Library, Trip Database, PDQ-Evidence, PubMed, and Science Direct were completed.The search included common terms related to vaccine effectiveness and safety for tuberculosis.Selection criteria: Randomized controlled trials comparing tuberculosis vaccines with placebo, in adults and children were screened for eligibility for compliance with inclusion criteria.Data collection and analysis: Clinical outcomes data were reported for adverse events, safety and immunogenicity endpoints with 95% confidence intervals (CI).Vaccine efficacies were reported however, none of the vaccines in this review achieved an efficacy rate higher than 17.3% (95% CI -31.9 to 48.2).Cytokine CD4 cell expression was observed.Main results: This review includes 7 group comparisons with data from 5 clinical trials.There was significant heterogeneity between studies with respect to study population size, testing validation methods, and baseline characteristics.There was also considerable statistical heterogeneity (I2 = 75.3%).None of the included studies demonstrated efficacy or effectiveness against Tuberculosis, the highest efficacy rate being 17.3% (95% CI -31.9 to 48.2).Positive Quantiferon conversion was observed at a rate of (RR, 2.72 95% CI 0.94, 7.85).Cytokine Positive CD4 T-cell expressing IFN-y growth was observed (Std.Mean Diff 1.92 95% CI 1.19 to 2.65) in 4 studies.There is potential in the tolerability of the vectors explored in this review possess to be potential delivery pathways for future vaccines in this disease area.
No takes yet. Share an insight, caveat, or question.
A 2016 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: